China Biopsy Market is expected to reach US$ 7.54 Billion by 2027. Since 2000, the number of cancer cases and deaths and the crude incidence and mortality of cancer have continuously climbed in China. Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests. Furthermore, China is attempting to address its fast-rising cancer burden. However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.
Trends in China Biopsy Industry Prevailing Currently:
China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer. These developments fuel a push for mass cancer screening and early detection among the 45 to 74-year-old group. As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.
Although imaging procedures such as X-rays and CT scans can help detect areas of concern, they cannot distinguish between malignant and noncancerous cells. Consequently, a biopsy is the only reliable approach to identifying most cancers for cancer diagnosis. To lower the cancer burden in China, biopsy screening technologies and procedures have been developed. However, the most viable option in the near future may be to provide coordinated screening for high-risk locations and opportunistic screening for non-high-risk areas.
Key Companies Insights:
Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are among the important players profiled in our report. These market players in China contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.
How COVID-19 Affected the China Biopsy Test Industry?
The Coronavirus outbreak hit hard for China’s biopsy diagnostics centers, hospitals, supply chain, and clinical trials. In addition, cancer diagnoses were being delayed, as they had been shut since the commencement of the COVID-19 pandemic, as diagnosis services and screening programs were put on halt.
Besides, during the pandemic, cancer patients also faced numerous challenges, including increased susceptibility to severe infection and interruptions in treatment or regular medical care. According to our results, the China Biopsy Test Market was negatively impacted from the end of 2019 to the beginning of 2020. However, according to our estimates, China Biopsy Market reached US$ 5.24 Billion in 2021 post recovery from the pandemic scenario.
Renub Research latest report “China Biopsy Market, Forecast By Market, Volume (Biopsy) & Diagnosed (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Leukaemia and Bladder), Application Insights (Market, Volume (Biopsy) and Diagnosed), Companies (Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc.)” provides a detailed analysis of China Biopsy Industry.
Application Analysis –the Market has been covered from 8 viewpoints:
1. Breast Cancer
2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
Furthermore, the above mentioned application analysis have been covered from 3 viewpoints:
2. Volume (Biopsy)
- Initiatives/Recent Developments
- Financial Insight
1. Becton, Dickinson and Company
2. Thermo Fisher Scientific Inc
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
7. Roche Diagnostics
8. Myriad Genetics Inc.
10. NeoGenomics Laboratories
11. Quest Diagnostics Inc.